Verici Dx (Verici Dx) Total Long-Term Assets : $3.68 Mil (As of Jun. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Verici Dx Total Long-Term Assets?

Total Long-Term Assets includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets. Verici Dx's Total Long-Term Assets for the quarter that ended in Jun. 2023 was $3.68 Mil.

Verici Dx Total Long-Term Assets Historical Data

The historical data trend for Verici Dx's Total Long-Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verici Dx Total Long-Term Assets Chart

Verici Dx Annual Data

Trend

Dec20

Dec21

Dec22

Total Long-Term Assets

2.23

2.79

3.98

Verici Dx Semi-Annual Data
	Jun21	Dec21	Jun22	Dec22	Jun23
Total Long-Term Assets	2.80	2.79	3.25	3.98	3.68

Verici Dx Total Long-Term Assets Calculation

Total Long-Term Assets are the sum of the carrying amounts of all assets that are expected to be realized in cash, sold or consumed longer than one year. It includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets.

Verici Dx Total Long-Term Assets Related Terms

Thank you for viewing the detailed overview of Verici Dx's Total Long-Term Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Verici Dx (Verici Dx) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Verici Dx PLC (OTCPK:VRCDF) » Definitions » Total Long-Term Assets

Comparable Companies

Traded in Other Exchanges

VRCI:UK

Address

19 Stanwell Road, Avon House, Penarth, Cardiff, GBR, CF64 2EZ

Website

https://www.vericidx.com

Verici Dx PLC is an immuno-diagnostics development company. The company is focused on developing diagnostics technologies which will help understand the outcomes of an organ transplant surgery. There are two products for clinical validation and commercialization: Clarava, which is a pre-transplant prognosis for the risk of early acute rejection; and Tuteva, a post-transplant diagnostic focused upon acute cellular rejection including sub-clinical rejection not being diagnosed through the current standard of care of rising serum creatine levels. The business of the Group comprises a single activity, that of the development of prognostic and diagnostic tests for kidney transplant patients.

Verici Dx (Verici Dx) Headlines

No Headlines